Figure 5.

STINGPOX induces anti-tumor effects in vivo. (A) Ovarian tumor explants were infected with STINGPOX or OncoVACV (1E4 PFU per tumor core), and qRT-PCR analysis was performed 72 hours post-infection to measure relative RSAD2 (n=3) and IFNB1 (n≥2) expression levels. (B) Mice bearing subcutaneous (SC) MC38 colorectal tumor, were treated with 3 doses intratumorally of PBS, OncoVACV, or STINGPOX intratumorally (IT) and anti-PD1 intraperitoneally (IP) as indicated in the timeline. Mouse survival plots are shown. (n=10 per group; *p<0.05; **p<0.005). (C) MC38 cells were infected in vitro with OncoVACV-GFP and STINGPOX (MOI = 1), and 48 hours post-infection, whole cell lysates were analyzed by WB for PD-L1 and disA (FLAG) expression. Ponceau staining of blot is shown for loading control. Data are shown as mean ± SEM.